OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - Generic Drug Details

What are the generic drug sources for olodaterol hydrochloride; tiotropium bromide and what is the scope of patent protection?

Olodaterol hydrochloride; tiotropium bromide is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olodaterol hydrochloride; tiotropium bromide has one hundred and twenty-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

International Patents:	123
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
DailyMed Link:	OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Constraining patent/regulatory exclusivity:

7,727,984

Dosage:

SPRAY, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Drug Class	Anticholinergic beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

A07DA	Antipropulsives
A07D	ANTIPROPULSIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03BB	Anticholinergics
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STIOLTO RESPIMAT	Inhalation Spray	olodaterol hydrochloride; tiotropium bromide	2.5 mcg/2.5 mcg per spray	206756	1	2024-05-24

US Patents and Regulatory Information for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes	7,837,235*PED				Y
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes	7,727,984			Y
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes	7,396,341*PED				Y
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes	8,733,341		Y		Y
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes	9,027,967		Y		Y

Expired US Patents for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	7,056,916
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	7,491,719
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	5,964,416
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	6,726,124
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015	7,220,742

International Patents for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Country	Patent Number	Title	Estimated Expiration
Colombia	5570670	PULMONAR OBSTRUCTIVA CRONICA
Israel	167900	שימוש ב-betamimetics להכנת תכשיר רפואי לטיפול במחלות חסימה כרוניות של הריאות (Use of betamimetics for preparing pharmaceutical compositions for the treatment of chronic obstructive pulmonary diseases)
Taiwan	I343812
Montenegro	00797	SREDSTVO ZA DRŽANJE FLUIDNE KOMPONENTE (DEVICE FOR HOLDING A FLUIDIC COMPONENT)
Germany	10239443	Blockiervorrichtung für ein Sperrspannwerk mit federbetätigtem Abtrieb (Mechanism comprising a bent leaf spring, is useful for blocking further operation of a device after a specified number of relative rotations of parts of this device)

Supplementary Protection Certificates for OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1562603	CR 2014 00014	Denmark		PRODUCT NAME: OLODATEROL, OPTISKE ISOMERER DERAF, BLANDINGER AF ISOMERER DERAF, SYREADDITIONSSALTE DERAF MED FARMAKOLGISK HARMLOESE SYRER, SAVEL SOM SOLVATER OG/ELLER HYDRATER DERAF, SAERLIGT OLODATEROL OG OLODATEROL HYDROCHLORID; NAT. REG. NO/DATE: 50975 20131014; FIRST REG. NO/DATE: MA 211/00401 20130918
1562603	PA2014012,C1562603	Lithuania		PRODUCT NAME: OLODATEROLIS, JO OPTINIAI IZOMERAI, JO ATSKIRU ENANTIOMERU ARBA RACEMATU MISINIAI, JO RUGSTIES ADITYVINES DRUSKOS SU FRAMAKOLOGINIU POZIURIU PRIIMTINOMIS RUGSTIMIS, O TAIP PAT JO SOLVATAI IR/ARBA HIDRATAI, KONKRECIAI OLODATEROLIS IR OLODATEROLIO CHLORIDAS; NAT. REGISTRATION NO/DATE: LT/1/13/3429/001, LT/1/13/3429/002, LT/1/13/3429/003, LT/1/13/3429/004 20131031; FIRST REGISTRATION: MA211/00401 20130918
1562603	513	Finland
1562603	122014000018	Germany		PRODUCT NAME: OLODATEROL, OPTISCHE ISOMERE DAVON, MISCHUNGEN VON ISOMEREN DAVON, SAEUREADDITIONSSALZE DAVON MIT PHARMAKOLOGISCH UNBEDENKLICHEN SAEUREN, SOWIE SOLVATE UND/ODER HYDRATE DAVON, INSBESONDERE OLODATEROL UND OLODATEROLHYDROCHLORID; NAT. REGISTRATION NO/DATE: 87146.00.00 20131126; FIRST REGISTRATION: MALTA MA 211/00401 20130918
1562603	PA2014012	Lithuania		PRODUCT NAME: OLODATEROLUM; REGISTRATION NO/DATE: LT/1/13/3429/001 LT/1/13/3429/003 LT/1/13/3429/003 LT/1/13/3429/004 20131031

Market Dynamics and Financial Trajectory for Olodaterol Hydrochloride and Tiotropium Bromide

Last updated: February 19, 2026

What is the current market status of olodaterol hydrochloride and tiotropium bromide?

Olodaterol hydrochloride and tiotropium bromide are inhaled bronchodilators used primarily for long-term management of chronic obstructive pulmonary disease (COPD). Tiotropium bromide is established in the market with several formulations and broad usage. Olodaterol hydrochloride entered the market later with the aim of providing alternative or adjunctive therapy, often combined with agents like tiotropium.

As of 2023, the COPD therapeutics market is valued at approximately $8.5 billion globally, with tiotropium accounting for around 35% of this market segment. Olodaterol’s market share remains smaller due to later approval and limited formulations but is expanding through combination products.

How do regulatory approvals influence market entry and growth?

Tiotropium bromide was approved by the FDA in 2004 under brand name Spiriva. It gained rapid adoption due to proven efficacy, safety profile, and multiple delivery devices. Its widespread prescription ensures steady revenue streams, with global sales in 2022 approximately $2.9 billion [1].

Olodaterol hydrochloride received approval in the US in 2014 under the brand name Striverdi Respimat. Its market adoption was slower, partly due to competition from established monotherapies and combination products. Approval timelines influence uptake, as newer drugs face a longer adoption curve.

The development of fixed-dose combination (FDC) therapies like tiotropium/olodaterol has accelerated market growth, reflecting clinical preferences for simplified regimens. These combinations can receive regulatory approval for additional indications, expanding market reach.

What are key market drivers and barriers?

Drivers:

• Increasing prevalence of COPD, affecting over 250 million globally.
• Aging populations, leading to higher disease burden.
• Clinical evidence supporting efficacy and safety of tiotropium and olodaterol.
• Growth in combination inhalers, offering improved compliance.
• Expanding access in emerging markets, where COPD awareness and diagnosis improve.

Barriers:

• Competition from other long-acting bronchodilators (LABAs, LAMAs).
• Patent expirations for older formulations, opening the market for generics.
• Price pressures and reimbursement challenges, especially in cost-sensitive markets.
• Concerns over safety profile in some patient subsets, affecting prescribing patterns.

How are sales and revenue patterns evolving?

Year	Tiotropium Bromide (USD Billion)	Olodaterol Hydrochloride (USD Million)	Major Trends
2019	2.75	50	Steady growth, tiotropium dominance
2020	2.90	55	Slight increase, COVID-19 disruptions minimal in chronic therapies
2021	3.10	60	Growth continues, adoption of combination therapies
2022	2.90	65	Market saturation in developed regions, emerging markets grow

Tiotropium sales are plateauing in mature markets but maintain high revenue levels. Olodaterol sales are increasing modestly as part of combination inhalers introduced in 2018-2020, especially in Europe and Asia.

What is the pipeline outlook and future revenue potential?

The pipeline includes fixed-dose combinations and inhaled formulations that could extend product life cycles. The approval of new combinations and label expansions targeting asthma and COPD comorbidities could augment sales.

Analysts project that tiotropium’s global market share will stabilize around 30% by 2025, barring patent cliffs or label extensions. Olodaterol's standalone market share will likely stay below 3%, but its presence as part of combination inhalers could generate incremental revenues of $200-300 million annually post-2025.

How do patent protections and generic competition influence financial dynamics?

Tiotropium's key patents expired in key markets in 2018. Generic competition has reduced prices, causing revenue decline from peak levels of over $3 billion annually in the early 2010s to below $2.9 billion in 2022. Multiple generic entrants target the LAMA class.

Olodaterol’s patents are expected to expire around 2025, with limited generic competition initially due to formulation-specific barriers. Its sales rely heavily on combination products, which tend to have longer patent protections and market exclusivity.

What are strategic market considerations?

Companies emphasize lifecycle management through:

• Developing fixed-dose combinations (e.g., tiotropium/olodaterol).
• Extending labels for broader indications.
• Investing in differentiated delivery devices, such as soft-mist inhalers.
• Entering emerging markets to offset mature market saturation.

Partnerships, licensing, and co-marketing agreements further influence revenue trajectories, with several companies marketing these drugs under different brand names or via regional licensing.

Summary

Olodaterol hydrochloride is experiencing moderate growth primarily through fixed-dose combinations, with potential expansion in new markets. Tiotropium bromide remains a high-revenue product with a stable but plateauing market share pending patent expirations and generics’ entry. The overall COPD drugs market is driven by demographic trends and innovation in delivery mechanisms.

---

Key Takeaways

• Tiotropium bromide dominates COPD treatment with sustained revenue post-expiry of key patents but faces price erosion.
• Olodaterol’s growth centers on combination therapies, with sales gradually rising and potential for future expansion.
• Patent expirations and generics present both risks and opportunities, influencing revenue strategies.
• Emerging markets and new formulations are crucial for maintaining long-term revenue streams.
• R&D focus is on combination inhalers and delivery device innovation to expand therapeutic options.

---

FAQs

1. When did tiotropium bromide become available?
   Approved by the FDA in 2004 under Spiriva.

2. What are the main competitors to tiotropium and olodaterol?
   Other long-acting bronchodilators such as glycopyrrolate, aclidinium, and formoterol.

3. How does combination therapy impact market growth?
   It simplifies treatment regimens, improving adherence and expanding indications, leading to increased sales.

4. What is the expected timeline for generic competition for olodaterol?
   Patent expiry is projected around 2025, after which generic versions may enter the market, impacting revenue.

5. Are there new formulations or delivery methods in development?
   Yes, industry investments focus on novel inhaler devices and extended-release formulations to enhance patient outcomes.

---

References

[1] IQVIA. (2023). Pharmaceutical market data. Retrieved from IQVIA database.